- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To assess prostate-specific antigen (PSA) and testosterone levels after continuous and intermittent androgen deprivation therapy and compare time to PSA progression.
Critère d'inclusion
- Histologically or cytologically confirmed adenocarcinoma of the prostate (PCa) meeting the following criteria: - Locally adv. (stage T3 or T4) PCa, N0 or N+, M0 with PSA >= 5 ng/ml, or - Relapsing PCa following radical prostatectomy for clinically localized PCa with a serum PSA of >= 0.4 ng/ml or, - Relapsing PCa following radiotherapy with a serum PSA of >= 1 ng/ml as compared to a previous reference value